Published in Cancer Weekly, June 7th, 2005
According to recent research from Canada, "The comparative analysis of analgesic interventions for cancer pain is greatly compromised by the lack of well-validated and clinically) acceptable tools, which allow a composite classification of pain and patient population characteristics."
"Although the ESS for cancer pain was developed for this purpose, clinical and research utility has been limited due to problems associated with the assessment of some items, especially in relation to definitions and terminology. To overcome these limitations, we designed a revised ESS (rESS) and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.